Twist Bioscience Corporation

TWST Healthcare Biotechnology

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue
+23.2%
EPS
−264.7%
Free cash flow
−7.23%
Total debt
0.00%

Quarter to June 2026, against a year earlier

129.86 22.92 −15.00%
Market cap
$10.1B
P/E
0.0×
Fwd P/E
−91.4×
Dividend yield
—
F-score
4/9
Altman Z
3.44
Beneish M
−2.30
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 4 4

+8 more TTM periods

ROE
(29.59%) (18.16%) (16.79%) (16.43%)
ROA
(20.78%) (12.78%) (12.29%) (12.37%)
ROIC
(30.83%) (29.07%) (30.78%) (33.33%)
Return on Tangible Assets
(43.69%) (25.83%) (23.31%) (22.59%)
Average Days of Receivables
54.99 57.18 46.67 55.27
Free Cash Flow per Share
(1.53) (1.54) (1.42) (1.26)
Free Cash Flow
(95.62) (95.04) (86.72) (75.63)
Other line items

Show all line items

Columns are period end dates